Indications for Pacemaker (Class I and IIa/b Recommendations)
- Sinus node dysfunction (SND) with symptomatic bradycardia
- Symptomatic chronotropic incompetence
- Required drug therapy causing symptomatic bradycardia
- SND with HR < 40 bpm; bradycardia and symptom connection unclear
- Unexplained syncope and EP study (+) for SND
- Conisder for minimal symptoms but HR < 40 bpm while awake
- Type II second-degree AV block, or complete third-degree AV block with:
- Bradycardia + symptoms
- Arrhythmias + required bradycardic meds
- Asymptomatic awake with pauses > 3 sec, Asymptomatic awake with v-rate < 40 bpm, Asymptomatic awake with infra-His conduction
- Asymptomatic awake with AF and > 5 sec pauses
- After catheter ablation of AV junction
- Post-operative AVB not expected to resolve
- Neuromuscular: myotonic dystrophy, Kearns-Sayre, Erb dystrophy, peroneal muscular atrophy
- Symptomatic bradycardia + second-degree AVB
- Asymptomatic bradycardia + type II second-degree AVB (narrow or wide QRS)
- Asymptomatic second-degree AVB at intra or infra His level on EP study
- Asymptomatic complete third-degree AVB with:
- V-rate < 40 bpm
- LV dysfunction
- Site of block below AV node
- Reasonable in V-rate > 40 and persistent
- First or Second Degree AVB with:
- Pacemaker syndrome
- Hemodynamic compromise
- Muscular dystrophy of any AV block, with or without symptoms
- Recurrence of AVB is expected after offending drug is withdrawn
- Advanced second-degree AVB or third-degree AVB
- Type II 2nd degree AVB
- Alternating Bundle Branch Block
- Syncope of unknown type after exclusion of other causes including VT
- HV > 100 msec, even if asymptomatic
- EP study with infra-Hisian block, even if non-physiological
- After STEMI with: persistent 2nd/3rd DAVB regardless of symptoms, transient infranodal AVB
- Carotid sensitivity causing syncope and ventricular asystole > 3 sec
- Hypersensitive cardioinhibition > 3 sec with syncope of unclear trigger
- Neurocardiogenic syncope (symptomatic!) and bradycardia on tilt-table testing
- Post-transplant hearts with inappropriate or symptomatic bradycardia (permanent)
- Post-transplant with syncope
- Post-transplant with bradycardia that limits cardiac rehab
- Symptomatic recurrent SVT that responds/terminates with pacing
- Prevention of pause-dependent VT
- Congenital long-QT patients at high risk
- Prevention of recurrent refractory AF in patients with SND
- HoCM with significant symptomatic outflow tract obstruction (at rest or provoked)
- Children with age-inappropriate bradycardia
- Congenital third-degree AV block in the infant with V-rate < 55 bpm or with congenital heart disease and a V-rate < 70 bpm.
Contraindications for Pacemaker
- Asymptomatic patients
- Symptoms and bradycardia clearly do not overlap
- Drugs causing bradycardia are not essential and can be changed
- Bradycardia and/or AV block associated with obstructive sleep apnea (OSA, reversible)
- Asymptomatic first-degree AV block
- Supra-Hisian Wenckebach block
- Reversible AV block: Lyme, drug toxicity, OSA, transient vagal tone changes
- Fascicular block without AVB (or only 1st degree AVB) and without symptoms
- Post-MI with: transient AVB above ventricle, transient AVB and only LAFB, only fascicular block, 1st dDAVB with BBB or fascicular block
- Asymptomatic hypersensitive neurocardioinhibition
- Avoidable vasovagal syncope (symptoms controlled by modifying behavior)
- Accessory pathway with antegrade rapid conduction
- Frequent/complex PVC/NSVT in the absence of congenital LQT
- Torsades de pointes
- Only for the prevention of AF
- Asymptomatic HoCM, Symptomatic HoCM without evidence of outflow tract obstruction
- Transient post-Op block in a child
- Asymptomatic 1st DAVB or fascicular block in child with congenital HD
—————————————————————————————————————————————
Indications for Cardiac Resynchronization Therapy
- LVEF ≤ 35% on GDMT, sinus, LBBB, QRS > 120 ms, NYHA II-IV
- LVEF ≤ 35% on GDMT, sinus, non-LBBB, QRS > 150 ms (120-150 possibly), NYHA III-IV
- LVEF ≤ 35% on GDMT, AF, V-pacing expected near 100%
- LVEF ≤ 35%, V-pacing expected > 40%
- NYHA I, only if LVEF ≤ 30%, in sinus, on GDMT, and LBBB QRS > 150 ms
- NYHA II non-LBBB, only if LVEF ≤35%, sinus on GDMT, and QRS > 150 ms
Contraindications for Cardiac Resynchronization Therapy
- NYHA I or II, non-LBBB, QRS < 150 ms
- < 1 year of expected survival with good functional capacity
—————————————————————————————————————————————
Indications for ICD Therapy
- Survivors of cardiac arrest after reversible causes excluded
- Structural HD + spontaneous sustained VT
- Syncope + positive EPS for VT/VF
- > 40 days post-MI with LVEF ≤ 35% and NYHA II-III
- Dilated cardiomyopathy LVEF ≤ 35% and NYHA II-III
- NYHA I, if LVEF ≤ 30%, > 40 d post MI
- NYHA I, if LVEF ≤ 35%, non-ischemic CMP
- Prior MI, LVEF ≤ 40%, EPS inducible VT/VF
- Unexplained syncope, significant LV dysfunction, non-ischemic DCM
- Sustained VT
- 1+ SCD risk factors:
- ARVC/D and 1+ risk factors
- LQT on beta blockers who have syncope or VT
- LQT and SCD risk factors
- Awaiting transplant at home
- Brugada Syndrome with syncope or VT
- CPVT on beta blockers who have syncope or VT
- Dx of: cardiac sarcoidosis, giant cell myocarditis, Chagas
- Syncope and advanced structural heart disease
- Familial cardiomyopathy associated with SCD
- LV non-compaction cardiomyopathy
- Congenital HD with syncope of undetermined origin and with either ventricular dysfunction or arrhythmias
Contraindications for ICD
- < 1 year expected survival with poor functional class
- Incessant VT/VF
- Psychiatric illness that interferes with symptoms/follow-up
- NYHA Class IV patients with drug-refractory congestive heart failure who are not candidates for cardiac transplantation or CRT-D.
- Syncope unknown cause and negative EPS for VT/VF
- VF or VT is amenable to surgical or catheter ablation (e.g., atrial arrhythmias associated with the Wolff-Parkinson-White syndrome, RV or LV outflow tract VT, idiopathic VT, or fascicular VT in the absence of structural heart disease)
- Completely reversible cause of VT/VF (acute MI, electrolytes, trauma, drugs)
- < 40 days post MI, < 90 days post-revascularization, < 90 days after HF GDMT
References
2012 ACC/AHA Guidelines for Device-Based Therapy
Disclaimer © 2015 www.markmccauleymd.com. All rights served.
Recent Comments